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Abstract: Results from several observational studies of
HIV-discordant couples and a randomized controlled trial
(HIV Prevention Trials Network 052) show that antiretro-
viral therapy (ART) can greatly reduce heterosexual HIV
transmission in stable HIV-discordant couples. However,
such data do not prove that ART will reduce HIV incidence
at the population level. Observational investigations using
ecological measures have been used to support the
implementation of HIV treatment for the specific purpose
of preventing transmission at the population level. Many
of these studies note ecological associations between
measures of increased ART uptake and decreased HIV
transmission. Given the urgency of implementing HIV
prevention measures, ecological studies must de facto be
used to inform current strategies. However, the hypoth-
esis that widespread ART can eliminate HIV infection may
have raised expectations beyond what we may be able to
achieve. Here we review and discuss the construct of the
exposure and outcome measures and analysis methods
used in ecological studies. By examining the strengths
and weaknesses of ecological analyses, we aim to aid
understanding of the findings from these studies to
inform future policy decisions regarding the use of ART
for HIV prevention.
Introduction
Ecological studies use observational data to examine relation-
ships between exposures and outcomes at the level of groups rather
than individuals [1]. When individual-level data are unavailable,
ecological studies can provide important insight into population-
level trends [2,3]. Ecological studies appeal to researchers and
policy-makers because they are inexpensive, use existing data, and
are applicable to a broad range of issues. However, statistical
models using only group-level data cannot evaluate person-level
details and are therefore unable to test etiological hypotheses [2,4–
6]. Further, because ecological studies often use separate data
sources to measure exposures and their potential effects, the link
between exposures and outcomes cannot be determined at the
individual level.
Concern over these limitations has focused on ‘‘ecological
fallacy,’’ in which associations detected at the population level are
mistakenly interpreted to reflect the experience of individuals in
that population [1]. The first study describing ecological fallacy
presented an analysis of literacy and immigration in the US, in
which states with higher proportions of immigrants were shown to
have higher average literacy rates [7]. An ‘‘ecologically fallacious’’
interpretation of this association would be that immigrants have
higher literacy rates than native-born individuals; in fact,
individual-level analysis shows lower literacy rates among immi-
grants. The best explanation for this particular population-level
observation is that immigrants tend to settle in sites where the
native-born individuals have higher literacy levels [7].
Despite their limitations, ecological studies play an important
role in generating hypotheses that can be tested in experimental or
individual-level observational studies [2,8]. For instance, ecological
analyses were successfully applied during the exploratory phases of
research on male circumcision to prevent HIV, in which
geographical associations between circumcision rates and HIV
prevalence [9–11] provided the foundation for two decades of
observational research [12,13] on the topic. All three randomized
clinical trials that followed were halted because of a readily
demonstrable reduction of HIV acquisition in circumcised men
[14,15]. A Cochrane review published in 2009 concluded that
male circumcision is a clinically viable HIV prevention strategy
[16].
Here we describe an illustrative set of observational studies that
use ecological measures to examine the population-level effects of
antiretroviral therapy (ART) on HIV transmission. We critically
review what these studies measure, how they measure it, and how
their findings are interpreted. These results are used to provide
insight into the strengths and limitations of this approach.
Review articles synthesize in narrative form the best available evidence on a topic.
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Ecological Studies of ART for HIV Prevention
The narrative of exploring the effects of treatment on prevention
shares similaritieswith the narrative formalecircumcision, thoughwith
a somewhat different chronology. The hypothesis that antiretroviral
agents can prevent sexual HIV transmission was suggested in 1988
shortly after the development of azidothymidine, which was found to
effectively penetrate the genital tract [17]. This report was followed by
more intensive study of the effect of newly developed antiretroviral
agents on HIV replication in the male and female genital tract [18–21].
In 1994, Musicco et al. observed that azidothymidine could reduce
transmission of HIV in a cohort of discordant couples by 50% [22].
Several clinical trials in the late 1990s showing that ART stopped
mother-to-child transmission lent further credibility to the potential use
of ART to prevent sexual transmission [23]. In 2000, a randomized
clinical trial, HIV Prevention Trials Network 052 (HPTN 052), was
launched to determine the magnitude and durability of the effect of
combination antiretroviral agents on the prevention of sexual
transmission of HIV [24]. After this trial was launched, several [25–
28], but not all [29], individual-level observational studies reported a
protective effect of ART against HIV transmission in serodiscordant
couples. In addition, many modeling exercises suggested varying
degreesofpopulation-levelpreventionbenefit frombroaderuseofART
[30], the most widely discussed of which predicted elimination of HIV
withinfiveyearsunderidealconditions[31].Thesemodelsarediscussed
inareviewbyEatonetal. [32] in the July2012PLoSMedicineCollection,
‘‘Investigating the Impact of Treatment on New HIV Infections.’’ A
third group of eight ecological studies examined the population-level
effectsofwidespreadARTonHIVincidenceusingecologicalmeasures,
and reported significant effects [33–38] in all but two cases [39,40].
These eight studiesare the focus of this review.Finally, in mid-2011, the
HPTN052investigatorsreporteda96%reductionofHIVtransmission
in heterosexual couples over the 1.7 years of follow-up [41].
The promise of ART to control—and perhaps even eliminate
[31]—HIV has mobilized calls from public health leaders to
integrate preventive and clinical applications of ART [42–45]. In
light of several trials showing markedly improved survival for those
initiating ART earlier in the course of disease, such initiatives often
emphasize the clinical benefits that early treatment can bring HIV-
infected persons [46,47]. However, numerous behavioral, epide-
miological, and programmatic challenges may well limit the ability
to translate the individual-level prevention benefits of ART to a
larger population [48–52]. As such, demonstration of a minimally
biased population-level benefit is critical. Not surprisingly, there is a
credible tension between the need for more randomized individual-
and community-level trials (also called cluster randomized
controlled trials), and the immediate scale-up of HIV treatment
to prevent the spread of HIV [53–55]. The arguments for
immediate and broader roll-out of ART for the sake of prevention
are based on the HPTN 052 study [41], observational studies of
transmission within HIV-discordant couples [25–29], ecological
reports [33–36], and modeling exercises [31,56–59].
In this report we examine eight influential ecological studies that
assess the population-level effects of ART on HIV transmission
(Table 1). Most of the studies are from North America
[33,34,36,38–40], with one set in Taiwan [35] and one in Australia
[37]. Each study uses an ecological measure of the exposure, such as
access to ART, or the outcome, such as HIV incidence, or both
(summarized in Table 1; further considerations detailed in Table 2).
Measuring Population Exposure to ART
The simplest way investigators have characterized ART
exposure in a population of HIV-infected persons is to use a
dichotomous ‘‘before/after’’ measure, as in the case of Fang et al.
[35] and Porco et al. [38], based on the time at which scale-up of
local HIV treatment policies improved access to ART. Other
investigators have used more detailed measures of ART exposure,
including Montaner et al. [33], who estimated the number of
HIV-infected persons known to be receiving ART in a population,
or Katz et al. [40], who used prevalence of ART use among all
identified HIV patients. How well these measures reflect actual
ART exposure of an entire HIV-infected population depends on
the extent to which some subpopulations remain ‘‘hidden’’ to
investigators. ART exposure of the entire HIV-infected population
can only be measured if every person with HIV infection can be
identified and their treatment status assessed.
The hypothesis that population ART usage will decrease HIV
incidence relies on the assumption that ongoing HIV care will
sustain viral suppression, which is essential to transmission
prevention [60]. However, large numbers of HIV-infected persons
are lost to follow-up along the path from testing to suppressive
treatment [61,62]; the US Centers for Disease Control and
Prevention recently estimated that only about 24% of the 1.2
million people in the US with HIV infection in 2010 were virally
suppressed (Figure 1) [61–63]. Even once in care, rates of
treatment refusal by eligible individuals can be substantial [64].
To address the shortcomings of measures that do not fully reflect
suppressive ART use, alternative metrics incorporate viral load
information, based on the well-understood relationship between
sexual transmission of HIV from infected individuals and viral
concentrations in their blood [65] and genital fluids [66]. One such
measure uses the proportion (or absolute number) of treated
individuals in a study population with undetectable viral load,
usually defined as having fewer than 400 copies/ml [33,37–39].
A related measure, community viral load (CVL), is used by Das
et al. [34], Montaner et al. [33], and Wood et al. [36], and is
defined as the total, mean [33,34], or median [36] viral load for a
particular group or geographic region in a given period of time
(usually a year). CVL may be a useful biomarker for describing
population-level treatment outcomes over time, particularly in
cases in which geospatial information about the patients’ primary
residence or point of medical care is available, allowing inves-
tigators to compare geographic disparities in CVL with other
predictive factors such as socioeconomic status or proximity to
health care programs [34,39]. However, because most CVL
measures rely on public health surveillance data [33,34,39], these
exposure measures reflect the treatment outcomes only for the
subset of the HIV-infected population who get tested for HIV, link
to care, and remain in care long enough to contribute such
measurements. Patients with acute infection unidentified by
serological testing are de facto not considered in the calculation
of CVL, but may well be expected to contribute disproportionately
to onward HIV transmission [67,68]. Additionally, the use of an
aggregate measure of viral load in a community cannot capture
other important drivers of HIV transmission, such as the
distribution of viral loads within the population, sexual and
drug-using behaviors, and the sexual or drug-use networks
through which these behaviors spread HIV.
Outcome Assessment: Tracking Population HIV
Transmission
Accurate assessment of HIV incidence is critical for evaluating
the population-level effect of interventions, but such assessment is
challenging. The simplest approach is taken by Law et al. [37],
who simply refer to HIV incidence trends cited in past publications
[37]. Another approach, taken by Montaner et al. [33], Das et al.
[34], and Castel et al. [39], estimates population-based incidence



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLoS Medicine | www.plosmedicine.org 3 July 2012 | Volume 9 | Issue 7 | e1001260
from information on newly identified cases, using new HIV
diagnoses as a direct proxy for new infections. Obviously, newly
diagnosed patients acquired HIV at some unknown earlier time,
and so they are not ‘‘incident’’ in the traditional use of the word.
Using new diagnoses as a proxy for incidence also misses
populations that do not seek testing and that may have lower
access to health care and a corresponding higher risk for
acquiring HIV [69,70]. Changes in the number of new HIV
diagnoses may reflect actual changes in incidence, but will also be
affected by changes in availability of services and testing
behaviors [71].
A second population-based incidence estimation method, used
by Fang et al. [35], back-calculates past incidence from new
diagnoses [35]. This method relies in part on assumptions of
uniform parameters for disease progression markers such as the
onset of AIDS symptoms or the proportion of newly diagnosed
Table 2. Summary of measures used and considerations for their use.
Measure Considerations
Exposure: trends in population-level exposure to suppressive
ART
Before/after ART Dichotomous measure does not quantify the level of suppressive ART use in a population
Prevalence of ART use Only represents the prevalence of ART use among populations in clinical care; does not
account for failure to achieve viral suppression
Portion of treated individuals with undetectable VL Only represents the portion of individuals with undetectable VL among populations in clinical
care
CVL Only represents VL among populations in clinical care; aggregate and mean values obscure
important differences in transmissibility among individuals
Outcome: trends in HIV transmission
New HIV diagnoses New HIV diagnoses do not necessarily represent incident cases.
HIV incidence via longitudinal cohort follow-up Individuals who enroll and stay in cohorts may have lower HIV incidence than those who do
not; choice of testing interval and assay can introduce bias
HIV incidence via laboratory-based methods for identifying recent
infections
Recent infections identified only among HIV-infected individuals who test; assays have low
specificity and can overestimate recent infections
HIV transmission rates (new cases per prevalent case-year) from
modified back-calculation approach
Sensitive to peculiarities of a population’s testing behavior, including frequent repeat testers
or variable rates of disease progression among identified cases
VL, viral load.
doi:10.1371/journal.pmed.1001260.t002
Figure 1. Estimated numbers of HIV-infected individuals in the US retained (and corresponding percentages lost) at various stages
of the test, link, and treat cascade. This figure is based on data from [61,62].
doi:10.1371/journal.pmed.1001260.g001
PLoS Medicine | www.plosmedicine.org 4 July 2012 | Volume 9 | Issue 7 | e1001260
individuals with CD4 cell count less than 200 cells/ml, although
variation in the rate of decline of CD4 cell count over time and
across gender, ethnicity, and HIV subtypes undermines the
validity of this method [72–74].
Laboratory assays to identify persons with recent HIV infection
can be applied to stored biospecimens collected in the course of
routine surveillance or epidemiological research studies and may
provide a more rigorous method to determine current HIV
incidence from new diagnoses. The serologic testing algorithm for
recent HIV seroconversion (STARHS) [75] derives current HIV
incidence from the prevalence of recent infections, based on the
assay window period, delineated by the seroconversion dates as
detected by the original HIV-1 antibody test and the STARHS
method, and adjusting for the estimated prevalence among non-
testers and the probability that HIV-infected individuals will test,
receive treatment, and/or have missing specimens. Although the
investigations that use this method take advantage of existing
surveillance data, as in the case of Das et al. [34] and Katz et al.
[40], logistical challenges in storing and tracking remnant blood
can affect the completeness of data. Furthermore, even relatively
new laboratory methods such as the detuned enzyme-linked
immunosorbent assay or the newer BED capture enzyme
immunoassay have been known to misclassify established infec-
tions as incident infections; therefore, results must be interpreted
with some caution [76]. The use of this approach has generally
fallen out of favor pending development of better laboratory-based
tests or algorithms [77].
In contrast to population-based methods, longitudinal cohort
follow-up data have also been used to define population incidence,
as in the analyses carried out by Wood et al. [36] and Porco et al.
[38]. Although long considered the gold standard of HIV
incidence estimation, cohort follow-up is not immune to bias,
such as that which can result from the choice of testing intervals
and HIV assay [78]. Moreover, cohort participants may be a poor
proxy for the rest of the population, especially if the individuals
who enroll and remain in the cohort have fewer risk behaviors
than their unobserved counterparts.
Identifying the Effects of ART on HIV
Transmission
The ultimate aim of these investigations is to determine
whether population-level ART exposure has affected HIV
transmission. Some investigators used inductive reasoning to
synthesize either their own results [38,40] or a combination of
their own results and other published reports [37]. The remaining
studies quantify the association by comparing transmission rates,
defined as the ratio of new cases to prevalent cases in an interval
of time, before and after introduction of ART [35], or by using
time series regression modeling [33,34,36,39]. Although these
methods of analysis differ considerably, it is worth consideration
that nearly every study arrives at the same conclusion: that
increased population exposure to ART leads to lower HIV
transmission (Table 3).
However, inaccurate assessment of exposures or outcomes can
generate bias [51]. Overestimating the decline in incidence, for
instance—perhaps because of an unrecognized change in testing
behaviors—could produce an upward bias in the estimated impact
of ART on HIV transmission. Additionally, statistical associations
do not show causation, and observed trends in HIV diagnoses may
be due to factors other than population-level exposure to ART.
For example, declines in HIV incidence in settings worldwide—
most of which started to occur before ART was available or could
be expected to have had an effect—have been ascribed to various
phenomena, including the saturation of HIV in high-risk groups
[79] and changes in sexual behavior in response to the HIV
pandemic [71,78]. Although the potential confounding effects of
changes in HIV-related risk behaviors have been widely acknowl-
edged, only one report, from Vancouver [36], formally controls for
them in a regression model (Table 3). By comparison, another
study from British Columbia attributes large numbers of averted
HIV infections among injection drug users (IDUs) to broader
uptake of ART in the community, but some have suggested that
the analysis underestimates the potential protective effects of other
HIV prevention measures directed at the same community [80].
Indeed, the protective effects of Vancouver’s safer injection sites
have been documented in the past [81,82]. Also, consistent ART
adherence may be difficult to sustain in IDUs [83], further
suggesting that factors beyond viral suppression may have
contributed to the reduction in HIV incidence in this population.
The ability of ART to visibly reduce the number of newly
diagnosed cases of HIV takes time, because most new diagnoses
are made years after infection occurs, and many patients present
with a reduced CD4 count, reflecting substantial progression of
HIV disease. But in some ecological studies, the effect of ART is
presumed to be almost immediate. In the report from British
Columbia [33], where combination ART was introduced in 1996,
the largest decrease in documented new HIV diagnoses took place
between 1997 and 2000, but it is reasonable to question whether
enough suppressive combination ART was immediately available
to most patients to explain this decline.
Alternative Results and Other Considerations
The comparative lack of reports investigating the ecological
effects of population-level ART in settings where rising incidence
rates have been detected [84,85] suggests potential publication
bias. It is also noteworthy that ecological studies of ART for HIV
prevention are almost exclusively from developed western settings,
likely because of the limited availability of surveillance data, viral
load measurements, or registry data in resource-constrained
settings.
Stable or rising HIV incidence among certain population
subgroups with ready access to ART suggests the possibility that
identified relationships between ART access and declines in HIV
diagnoses in the studies reviewed here may be overstated. For
example, HIV incidence (estimated by STARHS) increased and
then stabilized among voluntary testers in San Francisco between
1999 and 2006 [85], and model-estimated numbers of new HIV
infections among men who have sex with men (MSM) in British
Columbia increased by 13% from 2005 to 2008 [86]. In parts of
Australia, the number of HIV diagnoses among MSM between
2000 and 2006 doubled, although cohort data suggest that this
observation may be largely driven by new infections among older
MSM [87,88]. In Denmark [89] and the UK [90], incidence rates
among MSM have reportedly increased. In Canada, some
subgroups of IDUs have experienced rising HIV incidence,
including Aboriginals [91], women [92], and youth [93],
prompting a call for renewed prevention efforts [94].
More than 50 experimental studies of treatment as prevention
are in some stage of development, and more can be anticipated
[95,96]. Policy-makers often do not have the luxury of waiting
years for trial data, and all decisions take place under a certain
degree of uncertainty. To this end, several studies, including some
considered in this review, have successfully applied novel tools of
geospatial mapping and phylogenetic analysis to aid interpretation
of observational data. A study in the UK [97] used viral molecular
phylogeny to determine the single most likely transmitter among
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MSM, allowing the investigators to account for the higher
transmission probability of individuals with acute and early
infection. Other studies, including those from San Francisco [34]
and Washington, D. C. [39], used geospatial analysis to illustrate
the spatial distribution of HIV-infected individuals in communi-
ties. Most recently, investigators at the Africa Centre for Health
and Population Studies in South Africa have been able to identify
a relationship between the density of ART use and HIV
acquisition risk within a community by studying HIV incidence
in a longitudinal cohort of more than 16,000 individuals (personal
communication, F. Tanser). Additional strengths of this study
include the use of information about the patients’ primary
residence and attempts to control for at least some possible
confounders of the relationship between ART uptake and HIV
incidence in the same community.
Several large cluster randomized controlled trials are being
developed [98]. A team from the Harvard School of Public Health
AIDS Initiative, working with partners in Botswana, will target
Table 3. Analysis methods and conclusions regarding effects.
Author
(Year) Analysis Method Statistical Analysis Results Control for Confounders? Conclusions
Castel et al.
[39] (2011)
Negative binomial regression of
new diagnoses on mean CVL
No effect estimate given,
but lack of association
reported (p = 0.11)
No No association was found between




Poisson regression of new diagnoses
on changes in total and mean CVL;
meta-regression of estimated incidence
on changes in total and mean CVL
No effect estimate given, but
statistically significant trend with
new diagnoses noted (p = 0.003)
Notes reported trends in
rectal gonorrhea, but no
formal assessment
Reductions in CVL were associated
with a decrease in new HIV diagnoses,
but not with slight HIV incidence
decrease
No effect estimate given, but




Modified back-calculation to estimate
reduction in transmission rate (new
cases per prevalent case-year)
between pre- and post-HAART eras
Pre-HAART transmission rate
estimated as 0.391 new
infections per prevalent case
Secondary analysis of
concurrent trends in annual
reported cases of syphilis and
gonorrhea, but no formal
assessment
Provision of free ART was associated
with a 53% reduction in the estimated
HIV transmission rate
Post-HAART transmission rate
estimated as 0.184 new
infections per prevalent case
Katz et al.
[40] (2002)
Inferences drawn from observation
of concurrent changes in HIV
incidence rates, reported sexual
behavior, STI diagnoses, and ART
use among population in clinical care
— Secondary analysis of
concurrent trends in reported
risk behaviors and cases of
rectal gonorrhea among MSM,
but no formal assessment
ART impact on HIV transmission has




Inferences drawn from predicted
changes in prevalence of undetectable
VL among population in clinical care
and external reports of HIV incidence
— No Declines in predicted detectable VL
between 1997 and 2009 coincide with
reports of rising new diagnoses and





Poisson regression of estimated new
diagnoses on changes in median CVL
and numbers receiving HAART
Effect of 100 new patients
receiving HAART on estimated
new diagnoses predicted as
20.97 (95% CI 0.96–0.98)
Notes reported trends in
infectious syphilis, rectal
gonorrhea, and genital
chlamydia as proxies for sexual
risk behaviors; trends in
hepatitis C were also noted
as proxy for unsafe injecting
behaviors
Increased ART coverage and reduced
CVL are associated with a decreased
number of new HIV diagnoses
Effect of 1 log decrease median
CVL on estimated new diagnoses
predicted as 20.86 (0.75–0.98)
Porco et al.
[38] (2004)
Inferences drawn from trends in
annual HIV incidence based on
antibody testing and time period
(pre- versus post-HAART period)
as indicator of ART use
— Transmission probability
accounts for sexual risk
behaviors among surveyed
MSM
Wider availability of ART appears to




Unadjusted and adjusted Cox
proportional hazards regression of
time to seroconversion on median
CVL in the preceding six months
Unadjusted hazard ratio for
effect of median CVL on time to
seroconversion estimated as 3.57
(2.03–6.27) per log10 CVL increase
Adjusted model controlled for
needle sharing, unprotected
sex, ethnicity, daily heroin use,
and unstable housing
Median CVL predicts HIV incidence
independent of HIV risk behaviors
Adjusted hazard ratio for effect
of median CVL on time to
seroconversion estimated as 3.32
(1.82–6.08) per log10 CVL increase
CI, confidence interval; HAART, highly active ART; STI, sexually transmitted infection; VL, viral load.
doi:10.1371/journal.pmed.1001260.t003
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individuals with sustained, high plasma viral loads for immediate
treatment, a strategy that could have exponential public health
benefits [73]. A second group from the London School of Hygiene
& Tropical Medicine and Imperial College London plans to test
the feasibility and impact of a universal test-and-treat strategy
along with other combination prevention measures, including
male circumcision [99]. But clinical trials have their own
limitations, including time, cost, ethical challenges, and perturba-
tions to the underlying community that can cause bias. And there
is never a guarantee that approaches employed in a trial will prove
effective outside of the trial setting.
Conclusions
Suppressive ART prevents HIV transmission in stable, monog-
amous, heterosexual couples. While ART seems to hold great
promise as a public health tool, its population-level benefits have
not been proven. Although ecological studies can play an
important role in the development of new HIV prevention
strategies, they are methodologically limited to building justifica-
tion of further formal scientific inquiry into population-level effects
of the potential policies in question. They are therefore the first of
many steps in the path from science to policy, beginning with the
establishment of biological plausibility, and progressing to
assessment of an individual-level effect and then a group-level
effect. Though most policy decisions must be made under
conditions of uncertainty, the hypothesis that widespread ART
can eliminate HIV infection [31,100] may have raised expectations
beyond what can actually be achieved. Additionally, implementa-
tion of treatment as prevention is not without its risks, including the
rise of population-level drug resistance with the rapid uptake of
ART in the face of continued limited infrastructure, and increased
risk compensation by treated individuals who believe that treatment
alone may justify forgoing other forms of protection [101–103].
Although we expect an impact of ART at the population level,
the magnitude of the effect may not be as great as some hope;
measuring the impact of ART roll-out on HIV spread, as in
several planned cluster randomized controlled trials, therefore
remains a critical step. Much as combination prevention methods
are believed to be better than single interventions for HIV
prevention [104], all the methods available to determine the
benefits of prevention interventions, including ecological studies,
should be deployed. The results must be weighed and used with a
full understanding of the methods used to define the outcomes of
treatment of HIV infection for prevention of transmission.
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